SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

$401JK is trending as community members rally around its anti-establishment narrative, viewing it as a movement against traditional retirement systems. Buoyed by a strong and active community, the coin's mission is to challenge the status quo. Discussions revolve around its potential for significant growth and staking opportunities.

Alchemy Pay

ACH is trending with community members discussing its potential and expressing frustration over its price action. Some point to upcoming catalysts like new partnerships and the potential launch of Alchemy Chain. Others speculate on buyout or merger possibilities, while many are focused on short-term price movements and potential gains.

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

eXoZymes Inc.

eXoZymes ($EXOZ) is trending due to its advancements in cell-free biomanufacturing, particularly the 100-fold scale-up of NCT production with impressive efficiency. The community is focused on the potential of NCT in the nutraceutical and pharmaceutical markets, especially its role alongside GLP-1 drugs and in addressing liver health. Discussions also highlight the company's AI-driven approach and partnerships, positioning eXoZymes as a leader in sustainable biomanufacturing.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a breakout, referencing bullish chart patterns and a potential surge towards $110. Discussions include long-term potential, historical price comparisons, and its role as 'digital silver' in the crypto market, while some traders express frustration with recent price action and volatility.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Ligand Pharmaceuticals ($LGND) is trending due to recent analyst target price raises and positive ratings, highlighting an improved growth outlook. Community discussion points to potential pipeline valuation debates and upcoming catalysts, including key PDUFA dates and trial data releases. The stock's royalty-based business model and diversified biopharma strategy are also attracting attention.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

DESTINY TECH 100 INC is trending due to speculation surrounding a potential SpaceX IPO and DXYZ's significant holdings in the company, driving investor interest. The community is actively debating the fund's valuation relative to its net asset value and comparing it to other SpaceX investment options like EchoStar. Discussions also include DXYZ's other private tech holdings, such as OpenAI, and their potential impact on the stock's price.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca ($ORCA) is trending due to an explosive price surge following a $36M Upbit exchange hack, which triggered a short squeeze as traders aggressively shorted the token. Community members are actively discussing entry points and potential short-term gains, while also pointing to the project's ecosystem growth and accessibility improvements as bullish catalysts. Recent ecosystem developments like MetaMask integration and potential buybacks may be contributing to positive sentiment.

Grayscale Investments LLC - Grayscale Litecoin Trust

Grayscale Litecoin TR LTC

Grayscale Litecoin Trust ($LTCN) is trending as traders debate its correlation to Litecoin ($LTC) and potential ETF conversion, while also discussing its current premium. Community members are weighing the risks and opportunities, with some expressing frustration over its performance compared to the underlying asset and other Grayscale products. Bullish sentiment remains for a potential breakout, but bearish voices caution about premiums and the influence of specific figures.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending due to news around stablecoins and blockchain, with community members weighing the potential disruption to traditional payment networks. Some analysts highlight the company's proactive approach and investments in these areas, while others suggest the stock may be oversold. Bullish community members see any dip as a buying opportunity, citing Mastercard's strong fundamentals and historical performance.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

Mullen Automotive ($MULN) is trending amidst discussions about trading strategies, past reverse splits, and comparisons to other volatile stocks. The community is also debating the potential for a "pump and dump," while some investors are sharing information on settlement claims related to previous investor lawsuits. Some users are referring to it as a scam.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail investors are buzzing about Adial Pharmaceuticals after the company announced the issuance of a key U.S. patent, which strengthens its strategy in precision medicine for addiction treatment.&nbsp;The announcement sent shares soaring to $0.78 during Thursday’s session — the stock’s highest level since February.The patent, officially granted on April 15 by the United States Patent and Trademark Office (USPTO), covers a novel method of treating alcohol- and opioid-related disorders using Adial’s investigational therapy, AD04, in patients with specific genetic markers.The company’s approach positions AD04 as a targeted therapy — not a one-size-fits-all solution — marking a significant step forward in the personalized treatment of addiction.The newly issued patent outlines the administration of AD04 to individuals with serotonin-related gene variations, including genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR, along with SNPs rs1150226, rs17614942, and rs1176713.&nbsp;The claims also include dosing regimens customized to these genetic profiles — a key component of Adial’s precision medicine approach.In addition to alcohol use disorder (AUD), the patent extends to a wide range of related conditions, including alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disturbances, gambling disorder, and alcohol withdrawal.&nbsp;The retail trading community was quick to react on Stocktwits.&nbsp;Sentiment&nbsp;flipped to ‘extremely bullish’ amid ‘extremely high’ message volume, underscoring strong retail engagement.&nbsp;One user said, “Great news today sent it flying,” while another predicted the stock could jump 50% to 100% in after-hours or the following day, calling the initial 11% gain “a bargain.”<stembedurl>https://stocktwits.com/GracebyFaith/message/613308669</stembedurl><stembedurl>https://stocktwits.com/KING_CRUSH/message/613278365</stembedurl>That retail enthusiasm is complemented by positive analyst coverage. According to data from Koyfin, two of the three analysts covering Adial currently rate the stock a ‘Buy,’ with the third assigning a ‘Hold.’&nbsp;Notably, no analysts have issued ‘Sell’ or ‘Strong Sell’ ratings.Despite Thursday’s spike, Adial shares remain down 26.4% year-to-date, underperforming the broader market. In comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dirty needles are collected by outreach workers with St. Ann’s Corner of Harm Reduction as they participate in a weekly needle clean-up at a Bronx park that drug users often use on April 23, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Equity

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

ADIL
Adial Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ADIL News

ADILAdial Pharmaceuticals Inc